Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab in Pretreated Participants With Gastric Cancer
Status:
Recruiting
Trial end date:
2023-01-03
Target enrollment:
Participant gender:
Summary
Primary Objectives:
Part 1: to confirm the recommended tusamitamab ravtansine loading dose Q2W in combination
with ramucirumab in advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma
population
Part 2: to assess the antitumor activity of tusamitamab ravtansine loading dose Q2W in
combination with ramucirumab in advanced gastric or GEJ adenocarcinoma
Secondary Objectives:
- To assess safety
- To assess durability
- To assess progression-free survival (PFS)
- To assess the disease control rate (DCR)
- To assess the pharmacokinetics (PK)
- To assess the immunogenicity